Abstract:4125 Background: Hepatocellular carcinoma (HCC), a prevalent malignancy and a leading cause of cancer-related mortality, often exhibits a grim prognosis due to recurrence post-surgical treatment. Minimal residual disease (MRD) is deemed a crucial factor contributing to early relapse following radical surgery. Previous studies have indicated that circulating tumor DNA (ctDNA) may serve as a promising biomarker for evaluating MRD in various cancers. However, its applicability in liver cancer remains unclear. Methods: We prospective included 136 patients during 2019 to 2021 who underwent curative-intention surgery for HCC in Zhongshan hospital. Plasma samples (n=625) were collected prior to surgery, 1-month post-surgery, and during subsequent surveillance. Patient-specific somatic mutations were identified through whole-exome sequencing of tumor tissue. For each patient, 16 patient-specific somatic mutations were selected and employed to assess ctDNA through ultra-deep sequencing of plasma DNA. Results: The median follow-up period was 24 months. At the last follow-up, 45 (33.1%) patients relapsed. The preoperative ctDNA concentration was elevated in patients who experienced tumor relapse after surgical treatment compared to those didn’t relapse (median: 125 vs.8.4 mean tumor molecules/mL, P<0.001). Most of patients (80.9%) demonstrated a significant decrease in ctDNA concentration to negative levels after curative surgery. Those maintaining a positive postoperative ctDNA status faced a higher recurrence risk (HR=11.5, P<0.001). Throughout longitudinal follow-up, positive longitudinal ctDNA (positive in any point) was significantly associated with a higher recurrence risk (HR=69.3, P<0.001). The area under the curve of longitudinal ctDNA for predicting recurrence was 0.956, boasting a sensitivity of 93.3% and specificity of 97.8%. The median interval from the first positive longitudinal ctDNA to clinical recurrence confirmed by imaging test was 4 months. The predictive performance of longitudinal ctDNA for recurrence surpassed that of alpha-fetoprotein (0.956 vs. 0.680, P<0.001). Patients with positive longitudinal ctDNA experienced benefits from adjuvant therapy (HR=0.4, P=0.019). Moreover, a decrease or stability of ctDNA after adjuvant therapy indicated treatment response and delayed clinical relapse (HR=0.3, P=0.00012). Conclusions: Tumor-informed ctDNA proves to be a reliable indicator for MRD detection after surgical treatment for HCC, enabling the prediction and anticipation of recurrence before clinical manifestation. It plays a crucial role in guiding the application of adjuvant therapy and assessing treatment efficacy, thereby facilitating postoperative management and enhancing the precision of medical interventions.

The Diagnostic and Prognostic Usage of Circulating Tumor DNA in Operable Hepatocellular Carcinoma.

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Preoperative Serum Ctdna Predicts Early Hepatocellular Carcinoma Recurrence and Response to Systemic Therapies

Circulating tumor DNA in hepatocellular carcinoma: trends and challenges

Dynamical Detection and Characterization of Circulating Tumor DNA in Patients with Hepatocellular Carcinoma

Circulating Tumor DNA As an Emerging Liquid Biopsy Biomarker for Early Diagnosis and Therapeutic Monitoring in Hepatocellular Carcinoma

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments

Application of Plasma Circulating Cell-Free DNA Detection to the Molecular Diagnosis of Hepatocellular Carcinoma.

Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma

Molecular profiling of Chinese patients with advanced hepatocellular carcinoma using circulating tumor DNA.

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

Circulating Tumor Dna Profiling Reveals Clonal Evolution And Real-Time Disease Progression In Advanced Hepatocellular Carcinoma

Circulating Tumor DNA Correlates with Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma

Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity

Utilization of Tumor-Informed Circulating Tumor DNA in Detecting Minimal Residual Disease and Guiding Adjuvant Therapy in Liver Cancer.

Preoperative Evaluation of Microvascular Invasion with Circulating Tumour DNA in Operable Hepatocellular Carcinoma

Circulating Tumor DNA As a Potential Indicator of Tumor Load During Interventional Therapy of Unresectable Hepatocellular Carcinoma.

Using Circulating Tumor DNA As a Novel Biomarker to Screen and Diagnose Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis